Maxim Group Maintains Their Buy Rating on DelMar Pharmaceuticals (DMPI)

Maxim Group analyst Jason McCarthy maintained a Buy rating on DelMar Pharmaceuticals (DMPIResearch Report) yesterday and set a price target of $2.00. The company’s shares closed last Monday at $0.75, close to its 52-week low of $0.40.

According to, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -21.8% and a 25.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Lineage Cell Therapeutics.

DelMar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.29 and a one-year low of $0.40. Currently, DelMar Pharmaceuticals has an average volume of 695.4K.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DMPI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.